Helixmith Co., Ltd
084990.KQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$208.59B
Close$
$-2715.30
173.1% downside
Current Fair Value
173.1% downsideOvervalued by 173.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $208.59 Billion |
|---|---|
| Enterprise Value | $200.37 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-9.45 |
| Beta | 0.15 |
| Outstanding Shares | 46,046,888 |
Return
| Return on Equity | -1.16% |
|---|---|
| Return on Assets | -1.15% |
| Return on Invested Capital | -5.58% |
Valuation & Multiples
| P/E Ratio | -129.91 |
|---|---|
| PEG | -76.16 |
| Price to Sales | 71.44 |
| Price to Book Ratio | 1.24 |
| Enterprise Value to Revenue | 82.8 |
| Enterprise Value to EBIT | -25.87 |
| Enterprise Value to Net Income | -125 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$446.39
Average shareholder expectationRevenue Estimate
$883.00 M
Average shareholder expectationNext Earnings Call
Expected Date
November 18, 2026
EPS Estimate
$446.39
Average shareholder expectationRevenue Estimate
$883.00 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Helixmith Co., Ltd
44 employees
CEO: Sunyoung Kim D.Phil., Helixmith Co., Ltd is a biotechnology enterprise focused on discovering and advancing novel biopharmaceutical solutions for human diseases. The company maintains a comprehensive pipeline of innovative biologics and herbal therapies, addr...